Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: A study of paired plasma and cerebrospinal fluid isolates

AIDS Research and Human Retroviruses

Volumn 25, Issue 12, 2009, Pages 1297-1305

  Karlsson, Ulf ^a   Antonsson, Liselotte ^b   Repits, Johanna ^a   Medstrand, Patrik ^b   Owman, Christer ^b   Kidd Ljunggren, Karin ^a   Hagberg, Lars ^c   Svennerholm, Bo ^c   Jansson, Marianne ^a,d   Gisslén, Magnus ^c   Ljungberg, Bengt ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Department of Virology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD;

AMIDES; CD4 LYMPHOCYTE COUNT; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINE CCL5; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VIRAL LOAD;

EID: 73149096528     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0069     Document Type: Article

References (65)

1. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seventransmembrane, G protein-coupled receptor. Science 1996; 272:872-877. (Pubitemid 26154590)
2. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
3. Bieniasz PD and Cullen BR: Chemokine receptors and human immunodeficiency virus infection. Front Biosci 1998;3:44-58.
4. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, and Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32:364-370. (Pubitemid 24033896)
5. Tersmette M, de Goede RE, Al BJ, et al.: Differential syncytium- inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
6. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118(9):681-688.
7. Karlsson I, Antonsson L, Shi Y, et al.: Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004;78:11807-11815.
8. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, and Owman C: Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS 2003;17:2571-2579.
9. Karlsson I, Antonsson L, Shi Y, et al.: HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-2569.
10. Whitcomb JM, Huang W, Fransen S et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51(2):566-575.
11. Price RW, Navia BA, and Cho ES: AIDS encephalopathy. Neurol Clin 1986;4(1):285-301.
12. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, and Cleary P: The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239(4840):586-592.
13. Sönnerborg AB, Ehrnst AC, Bergdahl SK, Pehrson PO, Sköldenberg BR, and Strannegård OO: HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988;2(2):89-93.
14. Epstein LG, Kuiken C, Blumberg BM, Hartman S, Sharer LR, Clement M, and Goudsmit J: HIV-1 V3 domain variation in brain and spleen of children with AIDS: Tissue-specific evolution within host-determined quasispecies. Virology 1991; 180:583-590.
15. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, and Wolinsky SM: Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994;68:7467-7481.
16. Ohagen A, Devitt A, Kunstman KJ, et al.: Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 2003;77:12336-12345.
17. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, and Richman DD: In vivo compartmentalization of human immunodeficiency virus: Evidence from the examination of pol sequences from autopsy tissues. J Virol 1997;71:2059-2071.
18. Chiodi F, Valentin A, Keys B, et al.: Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. Virology 1989;173:178-187.
19. Koenig S, Gendelman HE, Orenstein JM, et al.: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233(4768):1089-1093.
20. Watkins BA, Dorn HH, Kelly WB, et al.: Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science 1990;249(4968):549- 553.
21. Ghorpade A, Nukuna A, Che M, et al.: Human immunodeficiency virus neurotropism: An analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol 1998;72(4):3340-3350.
22. Catani MV, Corasaniti MT, Navarra M, Nistico G, Finazzi- Agro A, and Melino G: gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. J Neurochem 2000;74:2373-2379.
23. Hesselgesser J, Taub D, Baskar P, Greenberg M, Hoxie J, Kolson DL, and Horuk R: Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 1998;8:595-598.
24. Zheng J, Ghorpade A, Niemann D, et al.: Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: Implications for human immunodeficiency virus type 1-associated dementia. J Virol 1999;73:8256-8267.
25. Price, RW and Staprans S: Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: Window into brain infection? Ann Neurol 1997; 42(5):675-678.
26. Takashima K, Miyake H, Furuta RA, et al.: Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother 2001; 45:3538-3543.
27. Dragic T, Trkola A, Thompson DA, et al.: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-5644.
28. Baba M, Nishimura O, Kanzaki N, et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96:5698-5703.
29. Gisslén M, Hagberg L, Brew B, Cinque P, Price RW, and Rosengren L: Elevated cerebrospinal fluid neurofilament protein predicts development of AIDS dementia complex. J Infect Dis 2007;195(12):1774-1778.
30. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
31. Antinori A, Arendt G, Becker JT, et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69(18):1789-1799.
32. Hagberg L, Andersson L-M, Abdulle S, and Gisslén M: Clinical application of CSF neopterin concentrations in HIV infection. Pteridines 2004;15:103-107.
33. Andersson LM, Svennerholm B, Hagberg L, and Gisslen M: Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. J Med Virol 2000;62:9-13.
34. Albert J and Fenyo EM: Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 1990;28:1560-1564.
35. Olde B, Sabirsh A, and Owman C: Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor. J Mol Neurosci 1998;11:127-134.
36. Lefebvre B, Formstecher P, and Lefebvre P: Improvement of the gene splicing overlap (SOE) method. Biotechniques 1995; 19:186-188.
37. Mild M, Bjö rndal A, Medstrand P, and Fenyö EM: Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. Virology 2006;350(1):58-66.
38. Repits J, Oberg M, Esbjornsson J, et al.: Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005, 86:2859-2869.
39. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, and Price RW: Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990;28:556-560.
40. Brew BJ, Dunbar N, Pemberton L, and Kaldor J: Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis 1996;174:294-298.
41. Fuchs D, Chiodi F, Albert J, et al.: Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989;3:285-288.
42. Sonnerborg AB, von Stedingk LV, Hansson LO, and Strannegard OO: Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989;3:277-283.
43. Abdulle S, Mellgren A, Brew BJ, et al.: CSF neurofilament protein (NFL)-a marker of active HIV-related neurodegeneration. J Neurol 2007;254(8):1026-1032.
44. Albright AV, Shieh JT, Itoh T, et al.: Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999;73:205-213.
45. Gorry PR, Bristol G, Zack JA, et al.: Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001;75:10073-10089.
46. He J, Chen Y, Farzan M, et al.: CCR3 and CCR5 are coreceptors for HIV-1 infection of microglia. Nature 1997; 385:645-649.
47. Shieh JT, Albright AV, Sharron M, et al.: Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol 1998;72:4243-4249.
48. Smit TK, Wang B, Ng T, Osborne R, Brew B, and Saksena NK: Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): Evidence for neurotropic HIV variants. Virology 2001;279:509-526.
49. Schmidtmayerova H, Alfano M, Nuovo G, and Bukrinsky M: Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: Replication is restricted at a postentry level. J Virol 1998,72:4633-4642.
50. Spudich SS, Huang W, Nilsson AC, et al.: HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: A survey of subjects with viremia. J Infect Dis 2005;191:890-898.
51. Di Stefano M, Monno L, Fiore JR, et al.: Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS 1998;12(7):737-743.
52. McArthur JC, McClernon DR, Cronin MF, et al.: Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42(5):689-698.
53. Gisslen M, Hagberg L, Rosengren L, et al.: Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: A combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2007;2:112-119.
54. Gisslén M, Fuchs D, Svennerholm B, and Hagberg L: Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999:21(4):271-276.
55. Jansson M, Popovic M, Karlsson A, et al.: Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996;93(26):15382-15387.
56. Jansson M, Backstrom E, Bjorndal A, et al.: Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol 1999;2:325-338.
57. Koning FA, Kwa D, Boeser-Nunnink B, et al.: Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003;188:864-872.
58. Gray L, Sterjovski J, Churchill M, et al.: Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005;337: 384-398.
59. Sterjovski J, Churchill MJ, Ellett A, et al.: Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007;4:89.
60. Repits J, Sterjovski J, Badia-Martinez D, et al.: Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 2008;379(1):125-134.
61. Pierson T, McArthur J, and Siliciano RF: Reservoirs for HIV- 1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000;18:665-708.
62. Letendre S, Marquie-Beck J, Capparelli E, et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(1):65-70.
63. Edén A, Price RW, Spudich S, et al.: Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007;196(12):1779-1783.
64. Yilmaz A, Price RW, Spudich S, et al.: Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 47(2):168-173.
65. Mori J, Mosley M, Lewis M, et al.: Characterization of maraviroc resistance in patients failing treatment with CCR5- tropic virus inMOTIVATE 1 andMOTIVATE 2. Program and Abstracts of the XVI International HIV Drug ResistanceWorkshop, June 12-16, 2007, St. Michael, Barbados (Abstract 10).